First Gaucher type 3 neurological drug approved
MDSpire News
November 18, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

The FDA approved venglustat (Infilbray) for neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg.
Venglustat crosses the blood-brain barrier and inhibits glucosylceramide synthase, reducing glucosphingolipid accumulation.
Approval was supported by a 52-week randomized trial of 43 patients aged 12 years or older with stable systemic disease after enzyme replacement therapy.
At week 52, venglustat improved a combined neurological assessment compared with enzyme replacement therapy, but the FDA announcement provided no numerical effect estimates.
Reported adverse effects included gastrointestinal symptoms and mood changes; serious psychiatric risks included suicidal ideation and behavior.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: